Safety Management of Anti-TROP2 ADCs in Patients with Breast Cancer

The review clearly distinguishes the safety profiles of two TROP2-directed ADCs: sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis. Relative to a generic view of TROP2-directed ADCs as one drug class, this work emphasizes that although the two agents share TROP2 targeting and topoisomerase I inhibition, they have distinct toxicity profiles, so safety management needs to be agent-specific. Evidence comes from a review-level integration of recent clinical and real-world evidence; the text summarizes toxicity features with phrases such as 'mainly associated with' and 'characterized by', without reporting specific sample sizes or effect sizes.

The differences in toxicity are attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake. This framework links clinically observed toxicity profiles to drug-design features, offering a mechanistic explanatory path for why agents sharing the same target behave differently. This is a review-level mechanistic synthesis, expressed in the text as 'reflect the integrated effects of', without original experimental data or quantitative comparisons.

Recent clinical and real-world evidence has refined preventive and supportive strategies, including G-CSF use, UGT1A1-informed risk assessment, steroid mouthwash, ophthalmological monitoring and early recognition of interstitial lung disease. It moves safety management from reactive handling of adverse events toward proactive prevention and monitoring, and incorporates pharmacogenomic information (UGT1A1) as part of risk assessment. Based on a review-level summary of recent clinical and real-world evidence; the text lists specific strategies but does not report effect sizes or controlled data for each.

When combined with immune checkpoint inhibitors, the toxicity profile appears mainly overlapping rather than entirely new. It provides a directional judgment for safety expectations in combination settings, suggesting that clinical management can largely follow the known toxicity framework of the individual agents. Expressed in the text as 'appears to produce mainly overlapping rather than entirely new toxicity profiles', a review-level preliminary judgment with cautious wording.

This article is positioned around safety management of TROP2-directed ADCs in breast cancer, applicable to patients receiving sacituzumab govitecan or datopotamab deruxtecan and their clinical management teams, covering both monotherapy and combination with immune checkpoint inhibitors. The management strategies and future directions it proposes (pharmacogenomics, longitudinal monitoring, patient-reported outcomes, artificial intelligence) provide a framework for subsequent validation and implementation in real clinical settings.

This is a review article and does not report specific incidence figures, sample sizes or effect sizes for each toxicity, nor controlled evidence for each supportive strategy; the judgment that toxicity profiles with immune checkpoint inhibitors are 'mainly overlapping' is cautiously worded and still needs more data. In addition, the loaded text is machine generated and may contain inaccuracies, and the reading scope for this task is incomplete, lacking figures and reference details, so further verification of specific data and evidence strength remains an open question.